The stock price of Dynavax Technologies Corp (NASDAQ: DVAX) has surged by 1.98 when compared to previous closing price of 13.63, but the company has seen a 0.80% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-03-06 that Opportunistic refinancing extends the maturity of most of existing debt with improved terms and reduces dilution to existing capital structure $225 million of convertible notes due in 2030 issued, including an exchange for the retirement of ~$185 million of existing convertible notes due in 2026 and ~$40 million of new money Dynavax repurchased ~$8 million of the Company’s common stock in connection with this transaction EMERYVILLE, Calif., March 6, 2025 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, has entered into privately negotiated exchange and subscription agreements (the “Exchange Agreements”) with a limited number of holders of its outstanding 2.50% Convertible Senior Notes due 2026 (the “2026 Notes”) and one new investor, pursuant to which the Company will issue $225 million aggregate principal amount of 2.0% Convertible Senior Notes due 2030 (the “New Notes”) comprised of (i) an exchange for the retirement of approximately $185 million in aggregate principal amount of existing 2026 Notes, and (ii) approximately $40 million of New Notes issued to existing holders and one new investor (the “Transactions”).
Is It Worth Investing in Dynavax Technologies Corp (NASDAQ: DVAX) Right Now?
The price-to-earnings ratio for Dynavax Technologies Corp (NASDAQ: DVAX) is above average at 79.56x, Company’s 36-month beta value is 1.25.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DVAX is 118.28M, and currently, short sellers hold a 16.01% ratio of that floaft. The average trading volume of DVAX on March 19, 2025 was 2.14M shares.
DVAX’s Market Performance
DVAX’s stock has seen a 0.80% increase for the week, with a 8.42% rise in the past month and a 7.01% gain in the past quarter. The volatility ratio for the week is 2.40%, and the volatility levels for the past 30 days are at 3.07% for Dynavax Technologies Corp The simple moving average for the last 20 days is 1.16% for DVAX stock, with a simple moving average of 15.99% for the last 200 days.
Analysts’ Opinion of DVAX
Many brokerage firms have already submitted their reports for DVAX stocks, with Goldman repeating the rating for DVAX by listing it as a “Sell.” The predicted price for DVAX in the upcoming period, according to Goldman is $12 based on the research report published on February 11, 2025 of the current year 2025.
Goldman, on the other hand, stated in their research note that they expect to see DVAX reach a price target of $20. The rating they have provided for DVAX stocks is “Neutral” according to the report published on February 01st, 2024.
JMP Securities gave a rating of “Mkt Outperform” to DVAX, setting the target price at $22 in the report published on September 27th of the previous year.
DVAX Trading at 5.59% from the 50-Day Moving Average
After a stumble in the market that brought DVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.99% of loss for the given period.
Volatility was left at 3.07%, however, over the last 30 days, the volatility rate increased by 2.40%, as shares surge +7.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.75% upper at present.
During the last 5 trading sessions, DVAX rose by +0.80%, which changed the moving average for the period of 200-days by +20.56% in comparison to the 20-day moving average, which settled at $13.74. In addition, Dynavax Technologies Corp saw 8.85% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DVAX starting from DAVID NOVACK, who proposed sale 14,020 shares at the price of $13.58 back on Mar 18 ’25. After this action, DAVID NOVACK now owns shares of Dynavax Technologies Corp, valued at $190,386 using the latest closing price.
Novack David F, the President & COO of Dynavax Technologies Corp, sale 32,764 shares at $14.39 during a trade that took place back on Mar 07 ’25, which means that Novack David F is holding 22,098 shares at $471,474 based on the most recent closing price.
Stock Fundamentals for DVAX
Current profitability levels for the company are sitting at:
- -0.01 for the present operating margin
- 0.82 for the gross margin
The net margin for Dynavax Technologies Corp stands at 0.1. The total capital return value is set at -0.0. Equity return is now at value 4.48, with 2.75 for asset returns.
Based on Dynavax Technologies Corp (DVAX), the company’s capital structure generated 0.3 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26. The debt to equity ratio resting at 0.43. The interest coverage ratio of the stock is -0.35.
Currently, EBITDA for the company is 45.7 million with net debt to EBITDA at 4.79. When we switch over and look at the enterprise to sales, we see a ratio of 6.79. The receivables turnover for the company is 5.91for trailing twelve months and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.80.
Conclusion
In a nutshell, Dynavax Technologies Corp (DVAX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
